Study Objectives: The CDC reported over 70,000 Americans died from a drug overdose in 2017, nearly doubling the number just 10 years earlier. This rise was dominated by opiate overdoses which accounted for 47,600 of these deaths. Opiate use disorder is a multifactorial problem involving many factors both inside and outside of the traditional health care domain. Contributing factors include frequency and duration of opioid prescriptions in the emergency department (ED). Increased rates of long-term opioid use are seen among patients treated by high-volume opioid prescribers in the ED.
of low doses of droperidol, and its effectiveness in treating acute migraine headaches in the emergency department (ED) as well for sedation. Our objective was to evaluate mortality and QTc prolongation among patients who received droperidol.
Methods: This was an observational cohort study of all droperidol administrations in the ED from 1/1/2012 through 4/19/2018 at an academic quaternary center with 77,000 visits. The primary endpoint was mortality within 24 hours of droperidol administration. Secondary endpoints included QTc length up to 6 months before droperidol and within 24 hours after droperidol administration. A random sample of 10% was manually reviewed to assess the accuracy of the electronic data retrieval. QTc>500 msec was considered prolonged in both males and females.
Results: Zero deaths attributable to droperidol administration were recorded within 24 hours from the entire cohort of 6,881 visits. Among the manually reviewed records (N¼796), the median droperidol dose was 0.625 mg, representing 52.1% visits with this dose. 40.5% (N¼322) of patients received a dose close to 2.5 mg, and 2.4% (N¼19) received 5 mg of droperidol. There were 2.9% (N¼23) documented cases of akathisia, that resolved with diphenhydramine in every case. Visits over the study time period with an ECG within 6 months before droperidol administration and within 24 hours following droperidol were reviewed. There were 2,080 patients with EKG obtained within 6 months prior and 1,631 with and EKG within 24 hours after administration. There were 77 patients who had a QTc 500 prior to droperidol administration, and 43 patients with an ECG within 24 hours following droperidol administration that demonstrated a QTc 500, including 8 with a QTc 500 within 6 months before droperidol.
Conclusion: We found no increased mortality among the 6,881 patients who received droperidol. QTc was prolonged in 0.7% of cases after droperidol administration, and this did not result in patient significant outcomes. Our study confirms the findings by The Clinical Guideline Committee of the American Academy of Emergency Medicine which found no evidence that low-dose droperidol was unsafe for use in the ED.
Potentially Inappropriate Medications Do Not
Clinically Impact Trauma Recidivism in the Elderly Study Objective: The study evaluated the association between potentially inappropriate medications (PIM) as defined by Beers' Criteria and the risk of trauma recidivism in the elderly. The American Geriatric Society (AGS) modified the list of PIMs in 2012 to include 19 categories of medications with limited effectiveness in the elderly but with a positive association with complications such as delirium, bleeding, fracture and falls, a major cause of elderly trauma. We hypothesized that the presence of PIM increases the risk of trauma recidivism.
Methods: This case-control study reviewed patients over age 65 evaluated at a single Level 1 Trauma center from February 1, 2013 through August 1, 2018. We performed a 1:1 propensity score matched analysis using age and sex between injured patients with one trauma evaluation at any level of trauma activation and those with more than one trauma evaluation during the study period. We used a receiver operating characteristic (ROC) curve to determine the number of PIM with a maximum predictive value for recidivism. Area under the curve (AUC) with 95% confidence intervals (CI) were calculated. We also evaluated if there were specific categories of PIM that were associated with recidivism using Chi square analysis. A p value of <0.05 was deemed significant.
Results: During the study period, there were 11,089 trauma evaluations meeting study criteria. 8252 patients had one trauma evaluation only and 2837 patients had more than one trauma evaluation for a 26.2% recidivism rate. Propensity matching resulted in 2324 patients in each group. Patients with one trauma evaluation and recidivists had similar mean number of total medications (12.34, standard deviation (SD) 6.71 vs 12.67, SD 6.83, p ¼ 0.09) but those with one trauma evaluation had a lower mean number of PIM (11.09, SD 6.74 vs 11.88, SD 6.99, p ¼0.001). ROC curve analysis showed that the maximum predictive threshold was 11 PIM (AUC ¼ 0.545, 95% CI¼0.529-0.560). In addition, analgesics, antidepressants, antiplatelets, antipsychotics, anxiolytics, central nervous system medication and stimulants were each significantly associated with recidivism (p <0.001 for all categories). Recidivists were on a greater mean number of medications in these seven categories than non-recidivists (6.45, SD 3.034 vs 6.15, SD 3.038, p ¼ 0.001) Conclusions: PIM are statistically associated with trauma recidivism in the elderly. However, of the 19 categories of PIM identified by the AGS, only seven were associated with recidivism. Moreover, as the mean number of PIMs differed by less than one between the two groups, the clinical significance of our findings is doubtful. We conclude that PIMs do not clinically influence trauma recidivism in the elderly. Study Objectives: Acute human immunodeficiency virus infection (AHI) represents a period of increased transmissibility of HIV. Identification of patients with AHI in the emergency department (ED) presents an opportunity to intervene in viral transmission through diagnosis and earlier treatment. Patients with AHI may display symptoms such as fevers, chills, fatigue, lymphadenopathy, myalgias, rash and/or diarrhea.
With current CDC screening guidelines, patients undergo an HIV Ab/p24 antigen test, then confirmatory HIV-1/2 Ab assay, and lastly a HIV viral load. Since only the HIV/p24 and the HIV-1/2 Ab assay are likely to result during an ED encounter, a high level of clinical suspicion is needed to differentiate AHI from false positives, who differ serologically by only the viral load. Such differentiation in the ED can lead to decreased time to treatment for AHI patients and unnecessary follow-up for false positives patients.
Methods: A retrospective chart review was performed on patients who presented to one ED between January 2017 and April 2019 who underwent HIV screening. Subjects were included with the following characteristics: positive screening HIV Ab/ p24 and negative confirmatory HIV-1/2 Ab assay. Qualitative analysis of the patients charts was done to differentiate AHI patients from false positive patients.
Results: During the screening period, 56 patients met inclusion criteria; 40 patients had an undetectable viral load and 16 patients had a detectable viral load. Patients with detectable viral load included 11 males and 5 females with mean age of 33.8. One or more risk factors for HIV transmission were reported in 12 unique patients: MSM (3), IV drug use (2), homeless (1), history of hepatitis C (1), multiple sexual partners (4), unprotected sexual encounters (3), known HIV+ sexual partner (1), and previous STI (2). The most common presenting symptom was subjective fevers (12), generalized abdominal pain (8), URI symptoms (8), and headache (6).
Seven patients had contact with outside health care in the week prior to presenting to the ED without HIV testing performed at that time. Of the twelve patients who reported subjective fevers, four patients were febrile. Six patients had lymphopenia, one patient had lymphocytosis, eight patients had thrombocytopenia, and four patients had CD4 < 500 cells/mm 3 . Other infectious diseases diagnosed during hospital stay included HHV-6 meningitis (1), coronavirus (1), syphilis (1), and giardia (1). Three patients were formally diagnosed with AHI by the emergency physician.
Seven patients were discharged home, three left against medical advice, and six were admitted. Of the patients not admitted, three returned within one week of initial ED visit with worsening symptoms.
Conclusion: Patients identified with AHI had 1+ known risk factor for HIV acquisition, normal/decreased white blood cell counts, subjective fevers but afebrile on presentation, or thrombocytopenia. Overall, these findings are encouraging that patients with AHI can be identified by history and laboratory testing during an ED encounter even when the confirmatory HIV Ab test is negative, prompting providers to order an HIV viral load and decreasing the time from positive test to initiation of antiretrovial medication.
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